X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: SIGA Technologies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 23, 2021
Details:
The strategic collaboration between Cipla and SIGA will provide the Biomedical Advanced Research and Development Authority (BARDA), a U.S. Department of Health and Human Services (HHS) department, with solutions for its biothreat and public health needs.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): COVID-19 vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 06, 2020
Details:
Premas Biotech has successfully completed the milestone of obtaining clones of all three coronavirus antigens, Spike, Envelope, and Membrane (M) that they have selected for their vaccine candidate.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
